The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the detection of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
The initiative utilises AI and machine learning (ML) technologies within the VisualDx platform, featuring BPDCN skin lesion images to aid clinicians in diagnosis.
Go deeper with GlobalData
Led by physicians, VisualDx enhances medical decision-making and education. Its tool has been adopted by 2,300 medical institutions.
The software provides a vetted database of clinical images to help healthcare professionals diagnose skin conditions.
The AI image search supports patient diagnoses across different stages of care and helps clinicians gain better knowledge.
Previously known as blastic NK-cell lymphoma, BPDCN is an aggressive orphan haematologic malignancy that manifests primarily through skin lesions and can affect multiple body systems.
Dermatologists often play a crucial role in detecting this condition through biopsies of suspicious lesions, which pathologists then examine for specific biomarkers indicative of the disease.
The only approved treatment for BPDCN in Europe, the US and other international markets is Tagraxofusp-erzs.
Menarini Group CEO Elcin Barker Ergun stated: “BPDCN often first presents as a skin lesion and usually has a poor prognosis. There is a dire need for early diagnosis so that patients may access appropriate treatment options.
“We are delighted to collaborate with VisualDx to provide healthcare teams with a tool using the latest AI/ML technology to help interpret challenging skin lesions.”
In January 2024, Menarini Group and Venatorx Pharmaceuticals signed an agreement involving the commercialisation of the antibiotic cefepime-taniborbactam in 96 nations pending regulatory clearances.
